New Clinical Trial Opportunity for Patients With Recurrent Glioblastoma
2015 is starting off with a bang, with a focus on brain cancer patients and new treatment options for recurrent glioblastoma (rGBM).
Happy New Year to each of you! 2015 is starting off with a bang, with a focus on brain cancer patients and new treatment options for recurrent glioblastoma (rGBM). I am delighted to finally be able to blog about a new clinical trial that is recruiting at the Seton Brain & Spine Institute in Austin, Texas and will soon be recruiting as well in Seattle, Washington. I am not at liberty to say more about the Seattle site at this time but can talk further about this trial in Central Texas. To learn more about the Seton Brain & Spine Institute, click here.
The principal investigator at Seton is Brian D. Vaillant, MD. The contact for this trial if you are interested in getting information and possibly participating is Heidi Herdon, RN, 513-324-7000, ext. 77713 (hherdon@seton.org). I am proud to say that Santosh Kesari, MD, director of neuro-oncology at Moores UCSD Cancer Center and one of CEF’s medical advisory board members, is the study director. To learn more about NCT02296580, click here.
Watch this video to learn about how the Nativis Voyager System works on solid tumors in canines. Findings from this study were so positive, the data were used to get human trials started for rGBM. I have eagerly been sitting on the sidelines watching this technology, the canine clinical trial results, and potential treatment for rGBM for the last 3 years. I am now delighted to see this potential new treatment for rGBM become available for brain cancer patients.
If you are in the central Texas area and interested in enrolling in this trial, please contact Heidi Herdon, and if you are in the Pacific Northwest and interested in learning more about this trial, including enrollment, please feel free to contact me directly at Dellann@ChrisElliottFund, at 425-785-8489, or at www.ChrisElliottFund.org.
2015 is already starting off with more and more treatment options for GBM patients. Let’s keep the momentum going!
Dellann Elliott Mydland is founder and president of the Chris Elliott Fund.
